



PRESS RELEASE

LAC Med bids for RM690.9 million worth of projects

- *Leverages market leadership to drive sales conversion and earnings momentum*
- *Declares final dividend of 0.65 sen per share in respect of FY2025*

Selangor, Malaysia, 18 May 2026 - MedTech solutions provider, LAC Med Berhad (LAC Med or the Group; Bloomberg: LACMED MK) sees increased tendering activities in the Malaysian healthcare services sector, as the Group's tender book stood at a high of RM690.9 million as at 30 April 2026, reflecting opportunities arising from the sector's rapid expansion.

As a leading MedTech player with 58% hospital coverage and more than 2,600 units of medical equipment installed nationwide, LAC Med is well-positioned to participate in even more tenders and to potentially convert its tender book to sales, driving the Group's profitability.

At its first Annual General Meeting today, Group Chief Executive Officer Mr. Liew Yoon Poh shared that LAC Med aims to leverage its market leadership to enhance clinical service quality, bolster domestic healthcare capabilities, and support Malaysia's ambition to achieve RM7 billion in medical tourism revenue by 2030.

"As the healthcare industry continues to evolve amid an increasingly dynamic global environment, LAC Med remains focused on disciplined execution, operational resilience, and long-term value creation.

Despite ongoing geopolitical and macroeconomic uncertainties, the Group continues to experience healthy demand across its core business segments, supported by its expanding installed base, recurring customer relationships, growing order book, and broadening portfolio of integrated healthcare solutions.

At the same time, we continue to strengthen the quality and visibility of its earnings by expanding recurring and consumables-based revenue streams alongside servicing, maintenance, and digital healthcare solutions. These initiatives are expected to deepen customer engagement, enhance operational resilience, and support the Group's long-term regional growth ambitions.

Backed by RM199.0 million order book as at 30 April 2026 and ongoing strategic initiatives, the Group remains confident in its long-term growth trajectory and optimistic on its prospects for FY2026."

Mr. Liew Yoon Poh (“刘任堡”)

Group Chief Executive Officer of LAC Med Berhad

LAC Med has a dividend policy to distribute at least 30% of its annual net profit to shareholders.



On 9 April 2026, the Group declared a final dividend of 0.65 sen per share in respect of the Financial Year Ended 31 December 2025 (FY2025), with the ex-date scheduled on 26 May 2026 and the payment date on 15 June 2026. The dividend payout is estimated to be RM2.6 million, marking the Group's first payout after its public listing in December 2025.

Prior to the public listing, the Group declared an interim dividend of RM5.0 million that was paid on 28 July 2025. Cumulatively, the total dividend payout amounts to RM7.6 million, representing a 35.2% payout ratio of the Group's net profit of RM21.9 million in FY2025.

First Quarter Ended 31 March 2026 (1Q26) Financial Announcement

In 1Q26, LAC Med recorded revenue of RM29.4 million and net profit of RM1.0 million. The Group's total revenue was derived from Supply of Medical Equipment of RM11.4 million, Supply of Related Products and Services of RM7.2 million, and Supply and Integration of Medical Devices of RM10.8 million.

While the Group's 1Q26 performance reflects normal quarterly timing differences in project deliveries and revenue recognition, the results remain aligned with management's operational expectations and strategic execution plans for FY2026.

There is no comparison to the preceding year's corresponding quarter ended 31 March 2025 as LAC Med was listed on the Main Market of Bursa Malaysia Securities Berhad on 10 December 2025.

Meanwhile, the Group's order book as at 30 April 2026 stood at RM199.0 million, providing earnings visibility for the coming financial periods.

Mr. Liew concluded: "Moving forward, the Group remains focused on securing higher-quality earnings through a balanced mix of integrated medical technology projects, recurring consumables supplies, maintenance services, and healthcare digital solutions. By strengthening our recurring and long-tail revenue streams, we aim to enhance earnings visibility, improve operational resilience, and build a more sustainable foundation for long-term growth."



About LAC Med Berhad (LAC Med; the Group)

Established in 2004, LAC Med is a leading medical devices and integrated solutions provider. Through its subsidiaries, LAC Med has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,600 units of medical equipment and supports over 300 active clients across Malaysia's healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med's competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia and Indonesia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

**Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd.
For media and investor relations enquiries, please contact:**

Mr. Terence Loo terence@aquilas.com.my

T:03-2711 1391/ M: 012-629 5618

Mr. Tee Wei Keat weikeat@aquilas.com.my

T:03-2711 1391/ M: 012-309 5448